Last two ozone-depleting inhalers being phased out

by Steven Reinberg, Healthday Reporter
Last two ozone-depleting inhalers being phased out
Deadline is Dec. 31, but FDA urges asthma patients to switch to eco-friendly versions now.

(HealthDay)—The last two inhalers to contain chlorofluorocarbons (CFCs), which deplete the ozone layer, will be removed from the market by Dec. 31, the U.S. Food and Drug Administration has announced.

That will complete the agency's long-running plan to phase out all of these types of inhalers, to comply with an international treaty that aims to protect the Earth's , the FDA said in a news release.

Inhalers typically are used to deliver the albuterol, which treats asthma and chronic obstructive pulmonary disease (COPD). More than 25 million people suffer from asthma, and another 15 million have been diagnosed with COPD, a serious lung disease that gets worse with time.

"CFCs were used as propellants to move the drug out of inhalers so that patients could inhale the medicine," Dr. Badrul Chowdhury, director of the Division of Pulmonary, Allergy and Rheumatology Products in the FDA's Center for Drug Evaluation and Research, said in a news release. "For more than two decades, the FDA and EPA have collaborated to phase out CFCs in inhalers—a process that included input from the public, advisory committees, manufacturers and stakeholders."

Although most inhalers using CFCs were phased out in 2008, two CFC inhalers remained: Combivent Inhalation Aerosol and Maxair Autohaler. Those who have asthma or COPD who use these inhalers should ask their doctor about alternative treatments, the FDA said.

For the most part, CFC inhalers have been replaced by inhalers powered by hydrofluoroalkanes (HFA), which are ozone friendly.

The FDA has approved three HFA-propelled albuterol inhalers: ProAir HFA, Proventil HFA and Ventolin HFA. An HFA-propelled inhaler containing levalbuterol, a medicine similar to albuterol, is available as Xopenex HFA, the agency said.

The discontinuation of CFC-propelled inhalers is the result of both the U.S. Clean Air Act and an international treaty known as the Montreal Protocol on Substances That Deplete the Ozone Layer.

More information: For more on inhalers, visit the U.S. Food and Drug Administration.

add to favorites email to friend print save as pdf

Related Stories

FDA phases out inhaler due to environmental impact

Sep 22, 2011

(AP) -- Asthma patients who rely on over-the-counter inhalers will need to switch to prescription-only alternatives as part of the federal government's latest attempt to protect the Earth's atmosphere.

Recommended for you

WHO: Millions of Ebola vaccine doses ready in 2015

20 hours ago

The World Health Organization says millions of doses of two experimental Ebola vaccines could be ready for use in 2015 and five more experimental vaccines will start being tested in March.

Added benefit of vedolizumab is not proven

Oct 23, 2014

Vedolizumab (trade name Entyvio) has been approved since May 2014 for patients with moderately to severely active Crohn disease or ulcerative colitis. In an early benefit assessment pursuant to the Act on the Reform of the ...

Seaweed menace may yield new medicines

Oct 22, 2014

An invasive seaweed clogging up British coasts could be a blessing in disguise. University of Greenwich scientists have won a cash award to turn it into valuable compounds which can lead to new, life-saving drugs.

User comments